Barclays raises Oruka Therapeutics price target to $160 on drug data

Barclays raised its price target on Oruka Therapeutics to $160 from $78 while keeping an Overweight rating, citing stronger conviction in ORKA-001 for psoriasis and positive readthrough to ORKA-002. The firm now models about $7 billion in peak sales for ORKA-001 and $2.6 billion for ORKA-002, with the stock recently trading at $80.80 after a 584% one-year surge. The bullish revision follows EVERLAST-A results showing 63.5% of patients achieved PASI 100 at Week 16.

Analysis

The market is now pricing ORKA less like a single-readout biotech and more like a platform with optionality across two assets, which is exactly where valuation can overshoot in the near term. The key second-order effect is not just higher peak-sales math, but the signaling value of a once-a-year maintenance profile: if credible, it materially widens the addressable market by improving adherence, payer acceptance, and physician switching economics versus chronic dosing competitors.

The bigger opportunity is that durability data is a de-risking event, while the current stock move is still largely an efficacy rerating. That creates a potentially asymmetric setup into the second-half update: if persistence is strong, you get a multiple expansion on both probability of success and terminal margin assumptions; if durability disappoints, the market can quickly compress the entire thesis because the stock has already pulled forward a large portion of success. In biotech terms, this is a classic transition from "beat-and-raise" to "prove-it".

The contrarian risk is that consensus may be underestimating how much is already embedded in sell-side targets after the huge rerating. When a name has moved this far, incremental positives often produce diminishing stock reactions unless the data changes the commercial model, not just the clinical narrative. The other hidden risk is competitive response: if a once-yearly IL-23 regimen looks real, larger incumbents with broader manufacturing, payer, and distribution leverage can respond faster than the market expects, narrowing the long-run opportunity set even if ORKA wins clinically.

Near term, the trade is still about event sequencing rather than fundamentals: the stock likely remains supported into the next catalyst window, but the risk/reward worsens if there is no fresh data for several months. The cleaner expression is to stay constructive into the durability update while avoiding chasing outright after the rerating, because the binary tail is now less about efficacy and more about whether the company can convert exceptional early biology into a durable commercial moat.

Key Decisions for Investors

• Stay long ORKA into the second-half durability update, but size as a catalyst trade rather than a core hold; target a 2-3 month window with upside driven by confirmation of once-yearly maintenance, and trim into strength if the stock gaps on hype rather than new data.
• For new risk, prefer ORKA call spreads over outright equity long; structure around the next clinical update to capture upside from a continued rerating while capping premium if the market has already over-discounted success.
• If holding ORKA common, hedge event risk with a partial collar into the next readout; the stock’s rerating makes downside on any durability miss meaningfully larger than incremental upside from another good-but-not-transformative update.
• Watch for a relative-value pair: long ORKA vs. short a basket of higher-priced commercial dermatology/immune franchises if durability data confirms differentiated dosing, since payer and physician switching pressure should hit weaker convenience profiles first.
• Do not chase ORKA after a large single-session move unless follow-through is accompanied by revised peak-sales or durability metrics; otherwise, the stock is vulnerable to a 15-25% post-event giveback typical of crowded biotech reratings.